首页|Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A Meta-Analysis

Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A Meta-Analysis

扫码查看
原文链接
  • NSTL
  • Karger
Introduction: The role of sarcopenia in malignant cutaneous melanoma is unclear. The aim of the present meta-analysis was to analyze the prevalence and clinical role of sarcopenia in patients with advanced cutaneous melanoma based on a large cohort. Methods: MEDLINE, Cochrane, and SCOPUS databases were checked for relationships between sarcopenia and clinical outcomes in melanoma up to September 2021. Overall, 6 studies including 719 patients met the inclusion criteria. The meta-analysis was performed using RevMan 5.3 software. Results: The prevalence of sarcopenia was 40.23%. Sarcopenia did not influence dose-limiting toxicity of treatment, hazard ratio (HR) 1.01, 95% CI (0.70–1.47). Sarcopenia was associated with lower progression-free survival (PFS): HR 1.49, 95% CI (0.98–2.26), and lower overall survival (OS): HR 1.67, 95% CI (1.11–2.52). Conclusions: The cumulative prevalence of sarcopenia in malignant cutaneous melanoma is 40.77%. Sarcopenia is slightly associated with PFS and OS and it is not associated with treatment toxicity.

Malignant melanomaSarcopeniaSurvivalToxicity

Alexey,Surov、Hans-Jonas,Meyer、Andreas,Wienke

展开 >

Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany

Department of Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany

Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle

2022

10.1159/000525928

Oncology

Oncology

SCI
ISSN：0030-2414
年,卷(期)：2022.100(9)
  • 1
  • 26